Loading
A phase 1 trial of Nelitolimod run by TriSalus Life Sciences, Inc., terminated.
Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma is a phase 1 interventional study registered as NCT04935229 by TriSalus Life Sciences, Inc., with 67 participants enrolled, started 2021-08-02, primary completion reached 2024-07-17. Conditions recorded: Metastatic Uveal Melanoma in the Liver. Interventions recorded: SD-101, Nivolumab, Ipilimumab, Nivolumab and Relatlimab. Reason given for stopping: The decision was made to terminate the study after the completion of Phase 1 enrollment and not proceed with Phase 2. Trial termination was not due to patient safety or data concerns.
Shares Nelitolimod, TriSalus Life Sciences and the tag pipeline.
Shares Nelitolimod, TriSalus Life Sciences and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/